SG11202106561RA - Crystalline forms of a par4 inhibitor - Google Patents

Crystalline forms of a par4 inhibitor

Info

Publication number: SG11202106561RA
Authority: SG; Singapore
Prior art keywords: crystalline forms; par4 inhibitor; par4; inhibitor; crystalline
Prior art date: 2018-12-21

Application number

SG11202106561RA

Inventor

Roxana F Schlam

Nicolas Cuniere

Victoria A Mbachu

Zhongping Shi

Petinka I Vlahova

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-21

Filing date

2019-12-20

Publication date

2021-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69187955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202106561R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-12-20 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2021-07-29 Publication of SG11202106561RA publication Critical patent/SG11202106561RA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SG11202106561RA 2018-12-21 2019-12-20 Crystalline forms of a par4 inhibitor SG11202106561RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862783223P	2018-12-21	2018-12-21
PCT/US2019/067717 WO2020132381A1 (en)	2018-12-21	2019-12-20	Crystalline forms of a par4 inhibitor

Publications (1)

Publication Number	Publication Date
SG11202106561RA true SG11202106561RA (en)	2021-07-29

Family

ID=69187955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202106561RA SG11202106561RA (en)	2018-12-21	2019-12-20	Crystalline forms of a par4 inhibitor

Country Status (29)

Country	Link
US (2)	US12129264B2 (en)
EP (1)	EP3898638B1 (en)
JP (1)	JP7473554B2 (en)
CN (3)	CN113227102B (en)
AU (2)	AU2019403348B2 (en)
BR (1)	BR112021011688A2 (en)
CA (1)	CA3124100A1 (en)
CL (1)	CL2021001590A1 (en)
CO (1)	CO2021008043A2 (en)
DK (1)	DK3898638T3 (en)
EA (1)	EA202191760A1 (en)
ES (1)	ES2964404T3 (en)
FI (1)	FI3898638T3 (en)
HR (1)	HRP20231527T1 (en)
HU (1)	HUE064830T2 (en)
IL (2)	IL284222B2 (en)
LT (1)	LT3898638T (en)
MX (1)	MX2021007417A (en)
MY (1)	MY206303A (en)
PE (1)	PE20211963A1 (en)
PL (1)	PL3898638T3 (en)
PT (1)	PT3898638T (en)
RS (1)	RS64900B1 (en)
SA (1)	SA521422311B1 (en)
SG (1)	SG11202106561RA (en)
SI (1)	SI3898638T1 (en)
SM (1)	SMT202300417T1 (en)
WO (1)	WO2020132381A1 (en)
ZA (1)	ZA202105115B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2841437T1 (en)	2012-04-26	2017-09-29	Bristol-Myers Squibb Company	Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation

2019
- 2019-12-20 HR HRP20231527TT patent/HRP20231527T1/en unknown
- 2019-12-20 JP JP2021535787A patent/JP7473554B2/en active Active
- 2019-12-20 US US17/415,237 patent/US12129264B2/en active Active
- 2019-12-20 EA EA202191760A patent/EA202191760A1/en unknown
- 2019-12-20 RS RS20231120A patent/RS64900B1/en unknown
- 2019-12-20 AU AU2019403348A patent/AU2019403348B2/en active Active
- 2019-12-20 CA CA3124100A patent/CA3124100A1/en active Pending
- 2019-12-20 CN CN201980085324.0A patent/CN113227102B/en active Active
- 2019-12-20 BR BR112021011688-5A patent/BR112021011688A2/en unknown
- 2019-12-20 IL IL284222A patent/IL284222B2/en unknown
- 2019-12-20 CN CN202510888947.9A patent/CN121021533A/en active Pending
- 2019-12-20 MX MX2021007417A patent/MX2021007417A/en unknown
- 2019-12-20 PE PE2021000917A patent/PE20211963A1/en unknown
- 2019-12-20 LT LTEPPCT/US2019/067717T patent/LT3898638T/en unknown
- 2019-12-20 PL PL19842497.0T patent/PL3898638T3/en unknown
- 2019-12-20 IL IL320212A patent/IL320212A/en unknown
- 2019-12-20 SM SM20230417T patent/SMT202300417T1/en unknown
- 2019-12-20 FI FIEP19842497.0T patent/FI3898638T3/en active
- 2019-12-20 WO PCT/US2019/067717 patent/WO2020132381A1/en not_active Ceased
- 2019-12-20 PT PT198424970T patent/PT3898638T/en unknown
- 2019-12-20 CN CN202510888950.0A patent/CN121021534A/en active Pending
- 2019-12-20 DK DK19842497.0T patent/DK3898638T3/en active
- 2019-12-20 ES ES19842497T patent/ES2964404T3/en active Active
- 2019-12-20 SI SI201930650T patent/SI3898638T1/en unknown
- 2019-12-20 EP EP19842497.0A patent/EP3898638B1/en active Active
- 2019-12-20 SG SG11202106561RA patent/SG11202106561RA/en unknown
- 2019-12-20 MY MYPI2021003475A patent/MY206303A/en unknown
- 2019-12-20 HU HUE19842497A patent/HUE064830T2/en unknown
2021
- 2021-06-17 CL CL2021001590A patent/CL2021001590A1/en unknown
- 2021-06-17 SA SA521422311A patent/SA521422311B1/en unknown
- 2021-06-18 CO CONC2021/0008043A patent/CO2021008043A2/en unknown
- 2021-07-20 ZA ZA2021/05115A patent/ZA202105115B/en unknown
2024
- 2024-10-08 US US18/908,888 patent/US20250026767A1/en active Pending
2025
- 2025-02-26 AU AU2025201372A patent/AU2025201372A1/en active Pending

Also Published As

Publication number	Publication date
PT3898638T (en)	2023-11-13
SI3898638T1 (en)	2023-12-29
CN121021533A (en)	2025-11-28
EP3898638A1 (en)	2021-10-27
PL3898638T3 (en)	2023-12-04
US20220064186A1 (en)	2022-03-03
IL284222B2 (en)	2025-09-01
EA202191760A1 (en)	2021-10-07
US20250026767A1 (en)	2025-01-23
LT3898638T (en)	2023-11-10
DK3898638T3 (en)	2023-11-20
CN113227102A (en)	2021-08-06
KR20210109559A (en)	2021-09-06
MY206303A (en)	2024-12-07
HRP20231527T1 (en)	2024-04-26
CO2021008043A2 (en)	2021-06-30
IL284222A (en)	2021-08-31
MX2021007417A (en)	2021-08-05
PE20211963A1 (en)	2021-10-04
AU2019403348B2 (en)	2024-11-28
AU2019403348A1 (en)	2021-08-05
CA3124100A1 (en)	2020-06-25
HUE064830T2 (en)	2024-04-28
SA521422311B1 (en)	2024-04-15
IL284222B1 (en)	2025-05-01
WO2020132381A1 (en)	2020-06-25
JP7473554B2 (en)	2024-04-23
JP2022514624A (en)	2022-02-14
CL2021001590A1 (en)	2021-12-03
BR112021011688A2 (en)	2021-09-08
CN121021534A (en)	2025-11-28
IL320212A (en)	2025-06-01
US12129264B2 (en)	2024-10-29
AU2025201372A1 (en)	2025-03-20
CN113227102B (en)	2025-07-18
ZA202105115B (en)	2024-02-28
FI3898638T3 (en)	2023-11-15
SMT202300417T1 (en)	2024-01-10
RS64900B1 (en)	2023-12-29
EP3898638B1 (en)	2023-08-30
ES2964404T3 (en)	2024-04-05

Publication	Publication Date	Title
IL285493A (en)	2021-09-30	Crystalline forms of an rsk inhibitor
ZA201903093B (en)	2020-11-25	Crystalline forms of a magl inhibitor
SG11202107225SA (en)	2021-08-30	Crystalline form of a cdk inhibitor
LT3972960T (en)	2026-03-25	Crystalline forms of a btk inhibitor
IL289929A (en)	2022-03-01	Crystalline forms of a cd73 inhibitor
SG11202105949RA (en)	2021-07-29	Crystalline forms and salt forms of a kinase inhibitor
GB201914860D0 (en)	2019-11-27	Inhibitor compounds
IL267821A (en)	2019-09-26	Inhibitors of nhe-mediated antiport
IL287630A (en)	2021-12-01	Solid forms of a glyt1 inhibitor
GB201819126D0 (en)	2019-01-09	Inhibitor compounds
IL290087A (en)	2022-03-01	Inhibitor compounds
GB201905328D0 (en)	2019-05-29	Inhibitor compounds
IL277806A (en)	2020-11-30	Growth inhibitor
IL285427A (en)	2021-09-30	Crystalline forms of a jak2 inhibitor
SI3891156T1 (en)	2024-03-29	New crystalline forms of a thienopyrimidine as mcl-1 inhibitor
IL292847A (en)	2022-07-01	Crystalline forms of a magl inhibitor
GB201819136D0 (en)	2019-01-09	Inhibitor compounds
IL279953A (en)	2021-03-01	Crystalline forms of a lta4h inhibitor
SG11202106561RA (en)	2021-07-29	Crystalline forms of a par4 inhibitor
IL291368A (en)	2022-05-01	Inhibitor of metadherin expression
GB201912411D0 (en)	2019-10-16	Crystalline forms of ivosidenib
GB201915908D0 (en)	2019-12-18	Crystalline forms of entrectinib
HK40015194A (en)	2020-08-28	Crystalline forms of a jak inhibitor compound
GB201905318D0 (en)	2019-05-29	Inhibitor compounds
GB201806131D0 (en)	2018-05-30	Inhibitor compounds